J Hillion
Overview
Explore the profile of J Hillion including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
61
Citations
814
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Azouz A, Wu Y, Hillion J, Tarkanyi I, Karniguian A, Aradi J, et al.
Leukemia
. 2010 Jan;
24(3):613-22.
PMID: 20072159
The expression of hTERT gene, encoding the catalytic subunit of telomerase, is a feature of most cancer cells. Changes in the chromatin environment of its promoter and binding of transcriptional...
2.
Abecassis I, Maes J, Carrier J, Hillion J, Goodhardt M, Medjber K, et al.
Leukemia
. 2007 Dec;
22(3):511-20.
PMID: 18094716
In the acute promyelocytic leukemia cell line, NB4, activation of the CD44 receptor triggers apoptosis. This pathway does not operate in the retinoid-maturation-resistant NB4-LR1 subclone. In this work, we show...
3.
Pendino F, Tarkanyi I, Dudognon C, Hillion J, Lanotte M, Aradi J, et al.
Curr Cancer Drug Targets
. 2006 Mar;
6(2):147-80.
PMID: 16529544
Telomeres are located at the ends of eukaryotic chromosomes. Human telomerase, a cellular reverse transcriptase, is a ribonucleoprotein enzyme that catalyzes the synthesis and extension of telomeric DNA. It is...
4.
Pendino F, Hillion J, Dudognon C, Delaunay J, Mourah S, Podgorniak M, et al.
Leukemia
. 2006 Feb;
20(4):599-603.
PMID: 16482212
Numerous strategies have been proposed to specifically inhibit telomerase (human telomerase reverse transcriptase (hTERT)) but to date only a few are clinically relevant in anticancer therapy. Recently, we have shown...
5.
Tarkanyi I, Dudognon C, Hillion J, Pendino F, Lanotte M, Aradi J, et al.
Leukemia
. 2005 Aug;
19(10):1806-11.
PMID: 16107885
Acute promyelocytic leukemia (APL) is efficiently treated with a cell differentiation inducer, all-trans retinoic acid (ATRA). However, a significant percentage of patients still develop resistance to this treatment. Recently, arsenic...
6.
Fuxe K, Agnati L, Jacobsen K, Hillion J, Canals M, Torvinen M, et al.
Neurology
. 2003 Dec;
61(11 Suppl 6):S19-23.
PMID: 14663004
Recently evidence has been presented that adenosine A2A and dopamine D2 receptors form functional heteromeric receptor complexes as demonstrated in human neuroblastoma cells and mouse fibroblast Ltk- cells. These A2A/D2...
7.
Torvinen M, Gines S, Hillion J, Latini S, Canals M, Ciruela F, et al.
Neuroscience
. 2002 Aug;
113(3):709-19.
PMID: 12150791
The role of adenosine deaminase in the interactions between adenosine A(1) and dopamine D(1) receptors was studied in a mouse fibroblast cell line stably cotransfected with human D(1) receptor and...
8.
Rybner C, Hillion J, Sahraoui T, Lanotte M, Botti J
Leukemia
. 2002 May;
16(5):940-8.
PMID: 11986958
The cellular prion protein (PrPc) is a sialoglycoprotein involved in the pathogenesis of prion diseases. It has been identified at the plasma membrane of several cell types. All-trans retinoic acid...
9.
Benoit G, Flexor M, BESANCON F, Altucci L, Rossin A, Hillion J, et al.
Mol Endocrinol
. 2001 Jul;
15(7):1154-69.
PMID: 11435615
On their own, retinoid X receptor (RXR)-selective ligands (rexinoids) are silent in retinoic acid receptor (RAR)-RXR heterodimers, and no selective rexinoid program has been described as yet in cellular systems....
10.
Belmokhtar C, Hillion J, Segal-Bendirdjian E
Oncogene
. 2001 Jun;
20(26):3354-62.
PMID: 11423986
Sensitivity of tumor cells to anticancer therapy depends on the ability of the drug to induce apoptosis. However, multiple signaling pathways control this induction and thus determine this sensitivity. We...